Risedronic acid vs ibandronic acid: a cost-effective analysis Clinical study 31 January 2013 Pages: 1 - 1
Preterm labour therapies for low-middle-income countries evaluated Clinical study 31 January 2013 Pages: 5 - 5
"An AIDS vaccine could greatly reduce the number of new infections and alter the course of the epidemic, Clinical study 31 January 2013 Pages: 6 - 6
Current guidelines reasonable for cervical infection in Madagascar Clinical study 31 January 2013 Pages: 6 - 6
Surgery economically preferable to medical management in GERD Clinical study 31 January 2013 Pages: 7 - 7
Pillbox organisers significantly improve adherence to antiretroviral therapy and virologic suppression in patients with HIV infections, Clinical study 31 January 2013 Pages: 7 - 7
“For Hong Kong, mammography may not be an efficient use of scarce public health dollars currently”, Clinical study 31 January 2013 Pages: 7 - 7
An interferon-γ release assay [T-SPOT.TB] is cost effective for the screening of close contacts before latent tuberculosis (TB) infection, Clinical study 31 January 2013 Pages: 8 - 8
ESA treatment lowers overall costs in CKD-related anaemia Clinical study 31 January 2013 Pages: 9 - 9
“There are gaps and significant variation” in the use of evidence-based, guideline-recommended therapies in patients with heart failure Media release 31 January 2013 Pages: 9 - 9
Educational interventions improve antimicrobial use in LTC facilities News item 31 January 2013 Pages: 10 - 10
The anaesthetic drug market is likely to reach $US4.3 billion due to new products and a growing, aging global population, Media release 31 January 2013 Pages: 10 - 10
Worldwide, the maternal mortality ratio is not declining fast enough to meet the Millennium Development Goal 5 Media release 31 January 2013 Pages: 10 - 10
A nonreimbursable charge will be added to every box of drugs sold in France. News item 31 January 2013 Pages: 11 - 11
Merck has been criticised by the AHF* over the announced price for its key new HIV/AIDS drug, raltegravir [Isentress]. Media release 31 January 2013 Pages: 11 - 11
The annual economic burden of the most common chronic diseases on the US economy is estimated at $US1.3 trillion Media release 31 January 2013 Pages: 11 - 11
The US FDA have introduced measures to attempt to increase the variety and availability of generic drug products. Media release 31 January 2013 Pages: 11 - 11